These insights underscore the novel mechanisms that highlight ACTN1's pivotal role in driving HNSCC progression and resistance to chemotherapy, suggesting ACTN1 as a promising therapeutic target in HNSCC management. This evidence concerns the gene ACTN1 and head and neck squamous cell carcinoma.